Novo Integrated Sciences Inc. Faces Delisting from Nasdaq, Begins Trading on OTC Market
Novo Integrated Sciences Inc. is facing delisting from Nasdaq due to a violation of the minimum bid price requirement. As of November 6, 2024, its stock will begin trading on the OTC Market under the symbol "NVOS." Nasdaq will file a Form 25 with the SEC to finalize the delisting, which will take effect 10 days after the filing. In the meantime, the company's stock will continue to be quoted on the OTC Market.
Novo Integrated Sciences Inc. recently announced a regulatory issue concerning its listing status on The Nasdaq Stock Market. The Nasdaq Listing Qualifications Staff notified the company of its violation of the minimum bid price requirement, leading to a decision to delist the company’s common stock. Consequently, as of November 6, 2024, Novo Integrated Sciences’ stock began trading on the OTC Market under the symbol “NVOS.” While Nasdaq plans to file a Form 25 with the Securities and Exchange Commission to finalize the delisting process, this filing has not yet occurred. The delisting will become effective 10 days after the Form 25 is filed, but the company’s stock will continue to be quoted on the OTC Market in the meantime. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Integrated Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-008349), on May 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
